Evistaraloxifene
According to the FDA label: Raloxifene hydrochloride tablet, USP is an estrogen agonist/ antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ). Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
14,488 adverse event reports submitted to the FDA (2003–2026)
Top Reported Adverse Events
The most frequently reported events in association with Evista in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Nausea 774 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →Fall 771 reports
A report that the person fell down. Falls are tracked because they can signal issues like dizziness, weakness, or balance problems.
Full definition in the glossary →Drug Ineffective 749 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →Pain in Extremity 717 reports
Pain in an arm or leg.
Full definition in the glossary →Pain 685 reports
A general report of physical discomfort, used when no more specific location is given.
Full definition in the glossary →Arthralgia 635 reports
Dizziness 613 reports
A feeling of being lightheaded, unsteady, or like the room is spinning.
Full definition in the glossary → See all drugs reporting this event →Muscle Spasms 585 reports
Sudden, involuntary tightening of a muscle, often called cramps.
Full definition in the glossary → See all drugs reporting this event →Fatigue 560 reports
Extreme tiredness or lack of energy that does not improve with rest.
Full definition in the glossary → See all drugs reporting this event →Headache 555 reports
Pain in the head or upper neck.
Full definition in the glossary → See all drugs reporting this event →- Body Height Decreased 532 reports
Back Pain 469 reports
Diarrhoea 465 reports
Loose or watery bowel movements, often frequent. Also spelled diarrhea in American English.
Full definition in the glossary → See all drugs reporting this event →- Bone Density Decreased 453 reports
Asthenia 451 reports
Physical weakness or lack of strength.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 14,111 |
| Male | 61 |
| Unknown | 13 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 18 |
| 18-34 | 6 |
| 35-49 | 169 |
| 50-64 | 2,529 |
| 65-74 | 3,018 |
| 75+ | 2,889 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Evista. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 6,279 |
| Other Serious | 5,763 |
| Hospitalization | 3,453 |
| Death | 558 |
| Disability | 468 |
| Life-Threatening | 317 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Evista. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2003 | 1 |
| 2004 | 1,125 |
| 2005 | 990 |
| 2006 | 855 |
| 2007 | 715 |
| 2008 | 758 |
| 2009 | 743 |
| 2010 | 793 |
| 2011 | 620 |
| 2012 | 758 |
| 2013 | 530 |
| 2014 | 554 |
| 2015 | 3,688 |
| 2016 | 471 |
| 2017 | 429 |
| 2018 | 325 |
| 2019 | 291 |
| 2020 | 205 |
| 2021 | 165 |
| 2022 | 145 |
| 2023 | 113 |
| 2024 | 99 |
| 2025 | 96 |
| 2026 (partial) | 19 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Evista
In FDA adverse event reports that mention Evista, these medications appeared most often in the same report.
- Levothyroxine (1,405 reports)
- Aspirin (1,264 reports)
- Ergocalciferol (1,175 reports)
- Teriparatide (1,173 reports)
- Atorvastatin (937 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026